Cargando…
A regulatory role for β-adrenergic receptors regarding the resolvin D1 (RvD1) pathway in the diabetic retina
Diabetic retinopathy is a visually debilitating disease with limited treatment options available. Compound 49b, a β-adrenergic receptor agonist, has been demonstrated to effectively reduce disease pathogenesis associated with diabetic retinopathy. While the exact mechanisms are not fully understood,...
Autores principales: | Shi, Haoshen, Carion, Thomas W., Jiang, Youde, Chahine, Adam, Steinle, Jena J., Berger, Elizabeth A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667888/ https://www.ncbi.nlm.nih.gov/pubmed/29095817 http://dx.doi.org/10.1371/journal.pone.0185383 |
Ejemplares similares
-
Lung Inflammation Resolution by RvD1 and RvD2 in a Receptor-Dependent Manner
por: Gao, Jin, et al.
Publicado: (2023) -
Expression and function of resolvin RvD1(n‐3 DPA) receptors in oral epithelial cells
por: Balta, Maria G., et al.
Publicado: (2022) -
β-adrenergic receptor agonist, Compound 49b, inhibits TLR4 signaling pathway in diabetic retina
por: Berger, Elizabeth A., et al.
Publicado: (2016) -
Resolvin D5 (RvD5) Reduces Renal Damage Caused by LPS Endotoxemia in Female Mice
por: Cardoso, Renato D. R., et al.
Publicado: (2022) -
Resolvin RvD2 reduces hypothalamic inflammation and rescues mice from diet-induced obesity
por: Pascoal, Livia B., et al.
Publicado: (2017)